Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Na Ryung Choi"'
Autor:
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background/aim In a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvat
Externí odkaz:
https://doaj.org/article/9d1effe635624ad0afe4ea20f7a60491
Autor:
Goh Eun Chung, Ju Yeon Kim, Hyunjae Shin, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Na Ryung Choi, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee
Publikováno v:
Diagnostics, Vol 12, Iss 7, p 1757 (2022)
Background: Hepatitis B virus (HBV) infection remains a threat to global public health. Serum hepatitis B surface antigen (HBsAg) has been used in screening for HBV infection. Quantitative HBsAg assays are useful for monitoring the natural history of
Externí odkaz:
https://doaj.org/article/b845d221257f49a585aa88f6cf41b270
Autor:
Jihye Kim, Ju Yeon Kim, Jeong-Hoon Lee, Dong Hyun Sinn, Moon Haeng Hur, Ji Hoon Hong, Min Kyung Park, Hee Jin Cho, Na Ryung Choi, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jin Chul Paeng, Hyo Cheol Kim, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Dongho Hyun, Jong Man Kim, Jung-Hwan Yoon
Publikováno v:
Journal of Nuclear Medicine. 63:1215-1222
The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial because of a high risk of recurrence after resection. This study aimed to compare long-term outcomes of transarterial radioembolization (TARE) with resection for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d13de23e92756589ca80fa2f58005d3f
https://doi.org/10.2967/jnumed.121.263147
https://doi.org/10.2967/jnumed.121.263147
Autor:
Jaekyu Noh, Hyeon Tae Kang, Yeon Lim Suh, Na Ryung Choi, Seungmin Lee, Hyukjin Kwon, Sang Bong Ahn, Dae Won Jun
Publikováno v:
Acta Scientifci Nutritional Health. 4:42-52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45054f8f901ed316e0ac30fa46e0ebe4
https://doi.org/10.31080/asnh.2020.04.0749
https://doi.org/10.31080/asnh.2020.04.0749
Autor:
Hee Jin Cho, Min Kyung Park, Jung Hwan Yoon, Yun Bin Lee, Na Ryung Choi, Ji Hoon Hong, Jeong Hoon Lee, Kwang-Woong Lee, Yoon Jun Kim, Suk Kyun Hong, Kyung-Suk Suh, Jeong Min Lee, Eun Ju Cho, Dongho Lee, Moon Haeng Hur, Jihye Kim, Joon Yeul Nam, Nam-Joon Yi, Su Jong Yu, Min-Seok Kim, Ju Yeon Kim
Publikováno v:
Cancers, Vol 13, Iss 6009, p 6009 (2021)
Cancers
Cancers; Volume 13; Issue 23; Pages: 6009
Cancers
Cancers; Volume 13; Issue 23; Pages: 6009
Simple Summary The effectiveness of surgical resection and radiofrequency ablation in early hepatocellular carcinoma is still controversial because previous studies show conflicting results. In addition, previous studies did not consider the antivira
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81808201771dcf16d4e77529cc6aa59b
https://www.mdpi.com/2072-6694/13/23/6009
https://www.mdpi.com/2072-6694/13/23/6009
Autor:
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Publikováno v:
BMC gastroenterology. 22(1)
Background/aim In a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvatinib as f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132f3a2d241d7e044f25784b552aa698
https://pubmed.ncbi.nlm.nih.gov/35337274
https://pubmed.ncbi.nlm.nih.gov/35337274
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:1877-1880.e3
Suppression of hepatitis B virus (HBV) replication with antiviral therapy (AVT) using nucleos(t)ide analogs reduces the risk of hepatocellular carcinoma (HCC) recurrence and prolongs survival after curative treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d191670a36a1f5330cb36a682a44ab
https://doi.org/10.1016/j.cgh.2022.02.014
https://doi.org/10.1016/j.cgh.2022.02.014
Autor:
Min Kyung Park, Yun Bin Lee, Hyemi Moon, Na Ryung Choi, Minseok Albert Kim, Heejoon Jang, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon
Publikováno v:
Digestive diseases and sciences. 67(10)
Lenvatinib and sorafenib are currently available to treat patients with advanced hepatocellular carcinoma (HCC). However, since the clinical trials evaluating the efficacy of lenvatinib and sorafenib included only patients with Child-Pugh class A, li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca7f3452ea4cc0ec3d25eb94d25c8588
https://pubmed.ncbi.nlm.nih.gov/35048224
https://pubmed.ncbi.nlm.nih.gov/35048224